The Contrived Mutant P53 Oncogene - Beyond Loss of Functions

Overview

Journal Front Oncol

Specialty Oncology

Date 2015 Dec 24

PMID 26697411

Citations 21

Authors

Kanaga Sabapathy

Affiliations

Soon will be listed here.

Abstract

Mutations in p53 are almost synonymous with cancer - be it susceptibility to the disease or response to treatment - and therefore, are a critical determinant of overall survival. As most of these mutations occur in the DNA-binding domain of p53, many of the clinical correlations with mutant p53 have been initially relegated to the loss of its transcription-dependent activities as a tumor suppressor. However, significant efforts over the last two decades have led to the vast knowledge on the potential functions of the mutated p53 protein, which have been attributed to the physical presence of the mutant protein rather than the loss of its wild-type (WT) functions. Beyond the inhibitory effects of mutant p53 on the remaining WT protein that leads to the dominant-negative effect in the heterozygous state, mutant p53's presence has also been significantly attributed to novel gain-of-functions that lead to addiction of cancer cells to its presence for survival, as well as for their ability to invade and metastasize, elevating it to a contrived oncogene that drives the cancer cells forward. This review will summarize the functional consequences of the presence of mutant p53 protein on cellular and organismal physiology.

Citing Articles

Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.

Kamath D, Iwakuma T, Bossmann S Nanomedicine. 2024; 56:102732.

PMID: 38199451 PMC: 11108594. DOI: 10.1016/j.nano.2024.102732.

Repeated Lineage Switches in an Elderly Case of Refractory B-Cell Acute Lymphoblastic Leukemia With Gene Amplification: A Case Report and Literature Review.

Takeda R, Yokoyama K, Fukuyama T, Kawamata T, Ito M, Yusa N Front Oncol. 2022; 12:799982.

PMID: 35402256 PMC: 8983914. DOI: 10.3389/fonc.2022.799982.

Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.

Annor G, Elshabassy N, Lundine D, Conde D, Xiao G, Ellison V Front Cell Dev Biol. 2021; 9:772315.

PMID: 34881245 PMC: 8645790. DOI: 10.3389/fcell.2021.772315.

in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.

George B, Kantarjian H, Baran N, Krocker J, Rios A Int J Mol Sci. 2021; 22(19).

PMID: 34639121 PMC: 8509740. DOI: 10.3390/ijms221910782.

Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.

Isermann T, Sener O, Stender A, Klemke L, Winkler N, Neesse A Nat Commun. 2021; 12(1):4019.

PMID: 34188043 PMC: 8242083. DOI: 10.1038/s41467-021-24064-1.

References

Gualberto A, Aldape K, Kozakiewicz K, Tlsty T . An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A. 1998; 95(9):5166-71. PMC: 20232. DOI: 10.1073/pnas.95.9.5166. View

Inga A, Cresta S, Monti P, Aprile A, Scott G, Abbondandolo A . Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis. 1997; 18(10):2019-21. DOI: 10.1093/carcin/18.10.2019. View

Serrano M, Lin A, McCurrach M, Beach D, Lowe S . Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5):593-602. DOI: 10.1016/s0092-8674(00)81902-9. View

Dittmer D, Pati S, Zambetti G, Chu S, Teresky A, Moore M . Gain of function mutations in p53. Nat Genet. 1993; 4(1):42-6. DOI: 10.1038/ng0593-42. View

Tan B, Tiong K, Choo H, Chung F, Hii L, Tan S . Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. 2015; 6:e1826. PMC: 4650736. DOI: 10.1038/cddis.2015.191. View

Lee M, Teoh W, Phang B, Tong W, Wang Z, Sabapathy K . Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell. 2012; 22(6):751-64. DOI: 10.1016/j.ccr.2012.10.022. View

Scian M, Stagliano K, Anderson M, Hassan S, Bowman M, Miles M . Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol. 2005; 25(22):10097-110. PMC: 1280285. DOI: 10.1128/MCB.25.22.10097-10110.2005. View

Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A . Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell. 2006; 10(3):191-202. DOI: 10.1016/j.ccr.2006.08.013. View

Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A . Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 2005; 25(2):304-9. DOI: 10.1038/sj.onc.1209026. View

10.

Noll J, Jeffery J, Al-Ejeh F, Kumar R, Khanna K, Callen D . Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene. 2011; 31(23):2836-48. DOI: 10.1038/onc.2011.456. View

11.

Girardini J, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E . A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011; 20(1):79-91. DOI: 10.1016/j.ccr.2011.06.004. View

12.

Blandino G, Levine A, Oren M . Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999; 18(2):477-85. DOI: 10.1038/sj.onc.1202314. View

13.

Muller P, Caswell P, Doyle B, Iwanicki M, Tan E, Karim S . Mutant p53 drives invasion by promoting integrin recycling. Cell. 2010; 139(7):1327-41. DOI: 10.1016/j.cell.2009.11.026. View

14.

Duan W, Gao L, Wu X, Hade E, Gao J, Ding H . Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS One. 2009; 4(5):e5563. PMC: 2680060. DOI: 10.1371/journal.pone.0005563. View

15.

Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J . Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994; 145(3):702-14. PMC: 1890319. View

16.

Hanel W, Marchenko N, Xu S, Yu S, Weng W, Moll U . Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 2013; 20(7):898-909. PMC: 3679454. DOI: 10.1038/cdd.2013.17. View

17.

Wolf D, Harris N, Rotter V . Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell. 1984; 38(1):119-26. DOI: 10.1016/0092-8674(84)90532-4. View

18.

Dearth L, Qian H, Wang T, Baroni T, Zeng J, Chen S . Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis. 2006; 28(2):289-98. DOI: 10.1093/carcin/bgl132. View

19.

Vikhanskaya F, Siddique M, Lee M, Broggini M, Sabapathy K . Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res. 2005; 11(12):4348-56. DOI: 10.1158/1078-0432.CCR-04-1547. View

20.

Haupt S, Di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A . Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res. 2009; 69(11):4818-26. DOI: 10.1158/0008-5472.CAN-08-4010. View